Department of Experimental Oncology, Istituto Europeo di Oncologia IRCCS, Via Adamello 16, 20 139 Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20 122 Milan, Italy.
Cells. 2019 Nov 7;8(11):1403. doi: 10.3390/cells8111403.
Acute myeloid leukaemia (AML) is a group of malignant diseases of the haematopoietic system. AML occurs as the result of mutations in haematopoietic stem/progenitor cells, which upregulate Wnt signalling through a variety of mechanisms. Other mechanisms of Wnt activation in AML have been described such as Wnt antagonist inactivation through promoter methylation. Wnt signalling is necessary for the maintenance of leukaemic stem cells. Several molecules involved in or modulating Wnt signalling have a prognostic value in AML. These include: β-catenin, LEF-1, phosphorylated-GSK3β, PSMD2, PPARD, XPNPEP, sFRP2, RUNX1, AXIN2, PCDH17, CXXC5, LLGL1 and PTK7. Targeting Wnt signalling for tumour eradication is an approach that is being explored in haematological and solid tumours. A number of preclinical studies confirms its feasibility, albeit, so far no reliable clinical trial data are available to prove its utility and efficacy.
急性髓系白血病（AML）是一组造血系统的恶性疾病。AML 是由于造血干/祖细胞发生突变引起的，这些突变通过多种机制上调 Wnt 信号通路。AML 中 Wnt 激活的其他机制包括通过启动子甲基化使 Wnt 拮抗剂失活。Wnt 信号通路对于白血病干细胞的维持是必需的。在 AML 中，有几种涉及或调节 Wnt 信号通路的分子具有预后价值。这些包括：β-catenin、LEF-1、磷酸化-GSK3β、PSMD2、PPARD、XPNPEP、sFRP2、RUNX1、AXIN2、PCDH17、CXXC5、LLGL1 和 PTK7。针对 Wnt 信号通路进行肿瘤清除是一种正在探索的方法，用于治疗血液系统和实体肿瘤。许多临床前研究证实了其可行性，尽管目前尚无可靠的临床试验数据证明其有效性和疗效。
